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Abstract 
 
mTOR signaling controls several critical cellular functions and is deregulated in many 
cancers, including pancreatic cancer. To date, most efforts have focused on inhibiting the 
mTORC1 complex. However, clinical trials of mTORC1 inhibitors in pancreatic cancer 
have failed, raising questions about this therapeutic approach. We employed a genetic 
approach to delete the obligate mTORC2 subunit Rictor and identified the critical times 
during which tumorigenesis requires mTORC2 signaling. Rictor deletion resulted in 
profoundly delayed tumorigenesis. Whereas previous studies showed most pancreatic 
tumors were insensitive to rapamycin, treatment with a dual mTORC1/2 inhibitor 
strongly suppressed tumorigenesis. In late-stage tumor-bearing mice, combined 
mTORC1/2 and PI3K inhibition significantly increased survival. Thus, targeting mTOR 
may be a potential therapeutic strategy in pancreatic cancer.  
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Introduction 
 
Pancreatic Ductal Adenocarcinoma (PDAC) accounts for 85% of cases of pancreatic 
cancer and is a highly aggressive form of the disease (1). Indeed, PDAC is predicted to 
become the second-leading cause of cancer death in the US by 2030 (2). At diagnosis, the 
disease is characterized by local invasion and distant metastases, so that even the few 
patients eligible for resection inevitably develop recurrent or metastatic disease (1). 
Most systemic therapies are ineffective, thus, PDAC is almost universally lethal, with a 5-
year survival of ~7% (3). Up until the recent adoption of combination chemotherapy 
regimens, FOLFIRINOX, and gemcitabine-Abraxane, gemcitabine monotherapy had been 
the standard-of-care for PDAC patients since 1997 (4). Yet, median survival with 
FOLFIRINOX or gemcitabine-Abraxane is 11 and 9 months respectively. Thus, PDAC 
presents a significant therapeutic challenge and novel, effective therapies are required.  
 
The genetic drivers of pancreatic cancer have been well-studied. Activating mutations in 
KRAS occur in ~90% of cases and are thought to be the initiating event driving the 
formation of precursor lesions termed pancreatic intraepithelial neoplasia (PanINs). 
Accumulation of further mutations in tumor suppressor genes, including CDKN2A, TP53, 
DPC4 and BRCA2 occurs throughout tumor progression (1). In fact, recent wide-scale 
genomic studies have revealed that 100s of genetic aberrations accrue (5). PDAC is also 
histologically complex, and interactions between tumor cells and the microenvironment 
contribute to tumor progression. Indeed, the extensive desmoplastic stroma that 
characterizes PDAC may protect tumor cells from a number of stresses, including 
chemotherapy, although this is somewhat controversial (6). Therefore, a greater 
understanding of the signals that drive tumor progression is required.  
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Activated KRAS drives a complex signaling network, involving multiple downstream 
effectors, including the MEK/ERK, PI3K/AKT and RAL pathways (7). The PI3K pathway 
regulates a number of processes integral to cancer, including cell growth, cell cycle 
entry, cell survival and metabolism (8). Indeed, PI3K signaling has been shown to be a 
key mediator of the effects of oncogenic KRAS in the pancreas (9). PI3K inhibitors have 
been developed for clinical trials, however, the pathway interacts with many other 
signals and there are several feedback loops making it difficult to predict the effects of 
pathway suppression (10).   
 
One of the major downstream effectors of PI3K signaling is mTOR, a serine/threonine 
kinase that acts as part of two distinct complexes (11). The mTORC1 complex, which 
includes Raptor, is responsible for several well-studied functions of mTOR, including 
sensing nutrient stress and regulating translation through interaction with p70S6K and 
4E-BP1 (11). p70S6K can also phosphorylate IRS1 on an inhibitory serine residue, thus 
causing negative feedback that inhibits insulin and IGF signaling to PI3K/AKT (12). 
Inhibition of mTORC1 can also lead to feedback activation of MEK/ERK signaling (13).  
 
The mTORC2 complex, which includes the essential subunit RICTOR, regulates cell 
growth, metabolism and survival, and organization of the actin cytoskeleton, through 
activation of AKT, SGK and PKC (14,15). We previously showed that high levels of 
phospho-AKTS473 in human PDAC were significantly associated with poor survival (16). 
More recently, RICTOR amplifications have been described in human lung cancers and 
melanomas (17,18). However, since the tumor promoting properties of mTORC2 
signaling have only recently been identified (19,20), a full understanding of the 
mechanisms underlying this effect is still developing. 
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Initial strategies to inhibit mTOR function focused on mTORC1 and the development of 
analogs of the mTORC1 inhibitor rapamycin. However, clinical trials using these 
compounds have proved disappointing (21). More recently, small molecule inhibitors 
that block mTOR kinase activity, and therefore impair both mTORC1 and mTORC2 have 
been developed. Not only do these inhibitors target both arms of mTOR signaling, they 
target 4E-BP1, and thus translational initiation, more efficiently than rapalogs, which 
primarily inhibit S6 kinase (22). We recently showed that pancreatic tumors in mice 
bearing mutations in Kras and Pten, a negative regulator of PI3K-mTOR signaling, were 
exquisitely sensitive to rapamycin whereas mice wild-type for Pten, but expressing 
mutant p53, were resistant (23). These findings suggest that mTORC2 signaling may 
play a critical role downstream of commonly occurring PDAC gene mutations and that 
inhibition of this complex may enhance therapeutic efficacy in PDAC.  
 
Global deletion of Rictor or Raptor in the mouse embryo results in embryonic lethality 
(20), however, conditional models of Rictor and Raptor deletion that allow interrogation 
of tissue-specific roles of mTORC1 and 2 are now available (20). We have utilized 
pancreas-specific deletion of Rictor to discern the requirement for mTORC2 signaling 
during pancreatic tumorigenesis. We show that genetic inactivation of mTORC2 
significantly blocks PanIN development, impairs progression to invasive carcinoma, and 
prolongs survival in a PDAC GEMM. Moreover, pharmacologic inhibition of mTOR 
extends survival, even in mice with late-stage disease. Our findings demonstrate an 
important role for mTORC2 signaling during pancreatic tumorigenesis and support the 
use of mTOR inhibitors as part of therapeutic strategies in PDAC. 
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Materials and Methods 
 
Animal Experiments 
Mice were maintained on a mixed background and given access to standard diet and 
water ad libitum. Ptf1a-cre, Pdx1-Cre, LSL-KrasG12D, Trp53R172H and Rictorflox mice have 
been described previously (24-27). Experiments were approved by UMass Medical 
School IACUC or performed under UK Home Office regulations and license approved by 
the local ethics committee. For more information see supplemental data. 
 
Caerulein injections 
Caerulein (50μg/kg, Sigma), or vehicle control (0.05M NH4OH in PBS) was injected 
intraperitoneally into 5-7-week old mice as previously described (28). 
 
In vivo treatment experiments 
Mice were randomly assigned to cohorts. Treatments were administered as follows: 
AZD2014 (AstraZeneca), in 20% w/v Captisol in H2O, at 15mg/kg by oral gavage (p.o.) 
daily; Gemcitabine (LC labs), in PBS, at 100mg/kg by intraperitoneal injection twice 
weekly; and AZD8186 (AstraZeneca), in 0.5% HPMC in H2O, at 50mg/kg p.o. twice daily.  
 
Histology 
Following necropsy pancreata were formalin fixed overnight, embedded in paraffin, and 
4-5-micron sections mounted on positively charged slides.  H&E and quadchrome 
staining was done as standard. A licensed pathologist blinded to genotype performed 
quantification of tissue area. See supplemental data for more information. 
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Immunohistochemistry 
IHC was performed on FFPE sections using standard protocols. For further details and 
antibodies see supplemental data and Table S1.  
 
RNAscope 
In situ detection of Rictor transcripts in FFPE mouse PDAC samples was performed 
using a Rictor specific RNAscope® assay (Advanced Cell Diagnostics, 1:5) according to 
the manufacturers protocol. 
 
Primary PanIN cell culture experiments 
Primary PanIN lines (isolated in the Bardeesy lab) (29) were grown on Laminin-coated 
plates as previously described (30) and infected with lentiviruses encoding Rictor or 
GFP-targeting shRNAs (Table S2). Viable cells were counted using trypan blue exclusion.  
SA-β-Galactosidase activity was assessed using a standard protocol. See supplemental 
data for more information. 
 
PDAC cell lines  
PDAC cell lines were generated in-house from KPC tumors as described previously (23). 
Testing was performed in-house to confirm that cells were mycoplasma-free. Cells were 
maintained at 37ºC and 5% CO2 in DMEM (Invitrogen) with 10% FBS (PAA), 2mM L-
Glutamine (Invitrogen), and 1% Penicillin/Streptomycin (Invitrogen). Cells were treated 
with AZD2014 +/- AZD8186. Cell viability was measured using the Cell Titer Blue assay 
(Promega).  
 
Synergy assay in PDAC cell lines  
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Mouse PDAC cell line K8484 (established in-house from a KPC tumor) and human PDAC 
cell line MiaPaca2 (from the European Collection of Cell Cultures, UK, in 2009 
(authenticated by STR genotyping)) were treated with AZD2014 +/- Gemcitabine for 
96h. Cell viability was determined by measuring total protein content using the 
sulforhodamine B assay. Combenefit software was used to analyze the data for potential 
synergy (http://www.cruk.cam.ac.uk/research-groups/jodrell-group/combenefit). 
 
Western Blotting 
Cell lysates were prepared and Western blot analysis was performed using standard 
protocols. Antibodies are listed in Table S3. 
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Results 
 
Loss of Rictor does not impair pancreas differentiation  
To determine the impact of mTORC2 inactivation on pancreas development, we 
generated mice lacking the essential mTORC2 subunit Rictor, specifically within the 
pancreas, by crossing mice bearing Ptf1a-cre and Rictorflox alleles (24,25) (Figure S1A). 
The absence of Rictor protein was confirmed by immunoblotting of protein lysates 
isolated from 2-month old pancreata (Figure S1B).  Mice lacking pancreatic Rictor were 
viable and showed no difference in body weight relative to their wild-type littermates 
(Figure S1C). However, Rictor null pancreata weighed significantly less than Rictor intact 
pancreata (Figure S1D).   Measurement of cell size (Figure S1E) and quantification of the 
total amount of genomic DNA as a surrogate measurement for cell number (Figure S1F), 
demonstrated that the reduced pancreas size likely results from decreased cell numbers. 
Histologically, Rictor null pancreata appeared normal, with the relative abundance of 
acinar, α- and β-cells similar to Rictor intact pancreata, as determined by 
immunostaining for the markers amylase, glucagon and insulin, respectively (Figure 
S1G). Glucose tolerance tests revealed that mice with Rictor null pancreata did show 
impaired glucose metabolism compared with wild-type littermates (Figure S1H). 
Importantly, however, mice with Rictor null pancreata were monitored for 500 days and 
did not exhibit any symptoms of ill health (n=11). 
 
mTORC2 deficiency impairs development and progression of KRASG12D-driven PanIN 
lesions  
Both 3-phosphoinositide-dependent protein kinase 1 (PDK1) and mTORC2 are required 
for full activation of AKT and SGK family members.  PDK1 is essential for the 
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development of KRAS-driven PanIN lesions and PDAC (9).  We therefore hypothesized 
that mTORC2 is similarly required for KRAS-driven tumorigenesis.  The well-established 
Ptf1a-Cre+/-; LSL-KrasG12D/wt mouse model develops PanIN lesions that mirror the human 
lesions that can progress to PDAC (31).  To investigate the role of mTORC2 signaling in 
this model, Ptf1a-Cre+/-;LSL-KrasG12D/wt;Rictorwt/wt (KC) and Ptf1a-Cre+/-;LSL-
KRASG12D/wt;Rictorfl/fl (KC RictorΔ/Δ) siblings were produced and their pancreata analyzed 
at 4 or 8 months of age.  Consistent with published studies, significant replacement of 
acinar cells by PanIN lesions containing abundant reactive stroma was evident in KC 
mice at 4 months of age (Figure 1A, B). In contrast, KC RictorΔ/Δ pancreata displayed 
fewer PanIN lesions and significant retention of acinar tissue (Figure 1A, B). Moreover, 
while KC pancreata displayed PanIN1B and PanIN2 lesions, precursors lesions observed 
in KC RictorΔ/Δ pancreata were restricted to PanIN1A. Quadchrome staining of the 
mucins produced by PanIN cells and collagen deposited by the reactive stromal cells, 
highlighted the differences between pancreata of the two genotypes (Figure 1A). 
Importantly, Rictor RNAscope showed that the PanINs arising in KC RictorΔ/Δ pancreata 
lacked Rictor RNA, ruling out the possibility that these cells had escaped recombination 
(Figure 1A). 
 
Acinar replacement in KC mice was nearly complete by 8 months and most PanIN 
lesions had progressed to PanIN2 (Figure 1C, D).  This KRAS-driven phenotype is 
significantly impaired in KC RictorΔ/Δ pancreata, with retention of acinar tissue, fewer 
PanINs and reduced reactive stroma (Figure 1C, D). Again, the PanINs present still 
lacked Rictor RNA (Figure 1C). Moreover, the PanINs present failed to progress beyond 
PanIN1 (Figure 1D). Together, these data indicate that Rictor deletion impairs the 
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development of KRAS-driven PanINs and blocks their progression to higher-grade 
lesions.  
 
Rictor null PanIN lesions display impaired mTORC2 signaling 
To determine the status of mTORC2 signaling in PanIN lesions, pancreata from 8-month 
old mice were stained for mTORC2 targets.  Relative to PanINs present in KC mice, KC 
RictorΔ/Δ PanINs displayed significantly reduced mTORC2 signaling, as measured by 
phospho-AKTS473 and phospho-NDRG1T346 (Figure 2). The reduced activity was specific 
to mTORC2 as PDK1-dependent phosphorylation of AKT on Thr308 was unaffected, as 
was phosphorylation of the mTORC1 target S6Kinase, and the MAPK signaling 
components ERK1/2 (Figure 2). Thus, the PanINs present in KC RictorΔ/Δ pancreata have 
not escaped Rictor gene deletion and develop in the absence of active mTORC2 signaling. 
 
Loss of mTORC2 signaling induces proliferative arrest 
The lack of compensatory activation of other signaling pathways and the limited 
progression of KC RictorΔ/Δ PanINs indicated fundamental phenotypic differences 
between KC and KC RictorΔ/Δ PanINs. We therefore compared the proliferation and 
apoptosis rates in PanINs of each genotype and found that the percentage of Ki67-
positive nuclei in KC RictorΔ/Δ PanIN1 lesions was significantly lower than in KC PanIN1 
lesions, at both 4 and 8 months (Figure S2A, B). Apoptosis rates, as assessed by cleaved 
caspase 3 staining, were very low in both genotypes and not different between the 
groups (Figure S2C, D). Together, these data suggest that mTORC2 inactivation impairs 
cell cycle progression in early PanIN lesions.  
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The cyclin dependent kinase (CDK) inhibitor p16Ink4a has been proposed as a barrier to 
KRAS-driven PDAC development (32).  We therefore assessed p16Ink4a expression in KC 
and KC RictorΔ/Δ PanIN lesions by immunostaining.  We found that the number of cells 
with nuclear localized p16Ink4a was significantly increased in KC RictorΔ/Δ PanINs, 
relative to KC PanINs, at both the 4- and 8-month time points (Figure 3A, Figure S3A). 
We also evaluated the CDK inhibitors p21Cip1 and p27Kip1 and found the number of 
p21Cip1- and p27Kip1-positive nuclei was similar between groups at the 4-month time 
point (Figure 3B, C; Figure S3B, C). However, we observed that while the number of 
positive nuclei decreased in PanIN lesions in 8-month old KC mice, they remained 
elevated in KC RictorΔ/Δ PanIN lesions (Figure 3B, C; Figure S3B, C). Thus, KC RictorΔ/Δ 
PanIN lesions display coordinate elevation of multiple CDK inhibitors. 
 
The concomitant elevation in p16Ink4a, p21Cip1, and p27Kip1 levels suggested the 
possibility that their expression may be regulated by a common factor. The polycomb 
repressor group complex 1 protein BMI1 is a negative regulator of p16Ink4a expression 
and has been implicated in p21Cip1 and p27Kip1 down-regulation (33). Moreover, BMI1 is 
required for Kras-driven PanIN formation and progression (34).  We therefore 
evaluated BMI1 expression in KC and KC RictorΔ/Δ PanIN1 lesions. We found that the 
percentage of cells with nuclear BMI1 staining was decreased in KC RictorΔ/Δ PanIN 
lesions relative to KC controls at both the 4-month and 8-month time points (Figure 3D, 
Figure S3D). 
 
We next sought to model the effect of mTORC2 inhibition in PanIN cells in an in vitro 
system. We performed shRNA-mediated knockdown of Rictor in two primary PanIN cell 
lines established from KC mice with early PanIN lesions (29). Rictor knockdown 
 14
significantly reduced proliferation in both cell lines and enhanced the expression of 
senescence-associated beta galactosidase (Figure 3E, F; Figure S3E). In contrast to our 
observations in vivo, however, we did not observe any changes in the expression of the 
CDK inhibitors p16Ink4a, p21Cip1 or p27Kip1, nor did we observe changes in BMI1 
expression (Figure S3F, G). It is possible that this difference is due to transformation in 
culture, given that these cell lines are able to form tumors when transplanted into 
immunocompromised mice. Taken together, our data suggest that Rictor knockdown 
impairs PanIN development and progression at least in part by robustly blocking cell 
proliferation.  
 
mTORC2 loss impairs PanIN progression following pancreas injury 
Pancreatitis is a major risk factor for the development of PDAC and can be modeled in 
mice using caerulein-induced pancreatic injury (28). To determine whether Rictor 
deletion impacted the response to injury we performed serial caerulein injections in 6-
week old wild-type and RictorΔ/Δ mice. Wild-type and RictorΔ/Δ mice displayed similar 
responses with stereotypical histologic changes - including acinar-to-ductal metaplasia 
(ADM), levels of which were not significantly altered by Rictor deletion, and increased 
separation of acinar lobules - evident 2 days following injection (Figure S4). As expected, 
injury was fully resolved by 21 days post-injection in wild-type mice, and also in RictorΔ
/Δ mice (Figure S4). These data suggest that Rictor is not required for pancreatic tissue 
repair, although it is possible that tissue repair could be delayed at earlier stages post-
injury.  
 
Expression of activated Kras enhanced the response to caerulein, with extensive ADM 
visible 2 days following treatment (Figure 4A). However, Rictor deletion blunted ADM 
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development (Figure 4A). Moreover, while KC mice evaluated 21 days following 
treatment displayed complete replacement of the pancreas parenchyma with PanIN 
lesions, many of which had progressed to PanIN1B and PanIN2, KC RictorΔ/Δ pancreata 
displayed significant retention of normal acinar tissue, and significantly fewer PanIN1B 
and PanIN2 lesions (Figure 4A, B).  
 
Evaluation of mTORC2 signaling via immunostaining for p-AKTS473 demonstrated that 
mTORC2 activity was impaired in KC RictorΔ/Δ lesions compared with KC lesions (Figure 
4C). By contrast, p-AKTT308 staining was equivalent between both genotypes (Figure 4C). 
Intriguingly, we observed that p-ERK staining was elevated in KC lesions relative to KC 
RictorΔ/Δ lesions, suggesting that mTORC2 signaling is required for activation of the 
MEK/ERK signaling cascade following injury-mediated PanIN progression (Figure 4C). 
To ascertain whether similar mechanisms mediate inhibition of PanIN progression in 
this model, we assessed the presence of nuclear CDK inhibitors p16Ink4a, p21 and p27. 
We found that KC RictorΔ/Δ lesions had elevated levels of these markers (Figure 4D-F, 
S5A-C). Moreover, CDK inhibitor levels inversely correlated with nuclear BMI1 
localization (Figure 4G, S5D).  
 
Assessment of CD45-positive infiltrating immune cells failed to show differences 
between KC and KC RictorΔ/Δ pancreata (Figure S5E). Further evaluation of the 
expression levels of inflammation associated genes using the Nanostring platform 
demonstrated differences between the pancreata of KC and KC RictorΔ/Δ mice injected 
with PBS (Figure S5F). Notably, macrophage associated genes, including Il6 and Stat3, 
which have been shown to be involved in macrophage-mediated inflammation in the KC 
mouse model, were reduced in the KC RictorΔ/Δ samples relative to the KC samples (35).  
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However, whilst these differences remained, they were not further enhanced following 
caerulein treatment (Figure S5F). Together, these data suggest that the absence of 
mTORC2 signaling impairs the progression of PanIN lesions following pancreatic injury. 
 
Rictor deletion delays tumor formation in KPC mice 
Our data above demonstrated that Rictor gene deletion severely impairs PanIN 
development and progression. To determine whether Rictor deletion inhibits the 
progression from PanIN to PDAC in an aggressive model of pancreatic tumorigenesis, we 
crossed Rictorfl/fl mice with KPC (Pdx1-Cre;LSL-KrasG12D/wt;LSL-Trp53R172H/wt) mice, to 
generate KPC RictorΔlΔ mice. We found that Rictor deletion dramatically delayed tumor 
formation in the KPC model, with median survival almost doubled in KPC RictorΔlΔ mice 
compared with KPC Rictor+/+ mice (Figure 5A). Further, 8 out of 47 KPC RictorΔlΔ mice 
sacrificed due to other pathologies were found to be tumor-free at over 200 days old. 
Deletion of one copy of Rictor was insufficient to affect tumor development (Figure 5A). 
Interestingly, we did not observe any apparent histological or pathological differences in 
the tumors that eventually developed in the KPC RictorΔlΔ mice compared with those in 
KPC Rictor+/+ mice. However, using RNAscope® we confirmed the absence of Rictor RNA 
demonstrating that the tumors were not derived from cells that failed to delete the 
Rictor locus (Figure 5B). These findings are supported by in vitro observations in murine 
PDAC cell lines in which Rictor knockdown impairs cell proliferation (Figure S6A-B, D-
E), and reduces anchorage independent growth (Figure S6C, F). 
 
We next examined the effects of Rictor deletion on mTOR targets by 
immunohistochemistry. Rictor deletion had no effect on phosphorylation of the mTORC1 
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signaling targets, S6 and 4E-BP1, but as expected, completely abrogated 
phosphorylation of the mTORC2 downstream specific targets pAKTS473 and pNDRG1 
(Figure 5C). We did not observe any differences in proliferation, as determined by Ki67 
staining, or in p21 expression, which is perhaps unsurprising in advanced tumors 
(Figure 5D). We did however observe slightly elevated nuclear p27 in KPC RictorΔlΔ 
tumors, and interestingly, decreased pERK, suggesting that in this system Akt activation 
does not result in Raf-MEK-ERK inhibition (Figure 5D). Taken together, our results show 
that mTORC2 signaling plays a significant role in pancreatic tumorigenesis and targeting 
mTORC2 could have therapeutic impact in this disease.  
 
Pharmacological inhibition of mTORC1/2 delays tumor formation in KPC mice  
To test this hypothesis we used AZD2014, a dual mTORC1/2 inhibitor recently 
investigated in a phase I clinical trial (36). We previously showed that KPC mice were 
resistant to treatment with rapamycin, and therefore not dependent on mTORC1 
signaling (23), however, AZD2014 allowed us to evaluate the impact of inhibiting both 
mTOR signaling complexes using a clinically relevant inhibitor.  We first tested AZD2014 
in vitro using KPC tumor cell lines and showed that signaling downstream of both 
mTORC1 and mTORC2, assessed by immunoblotting for pAKTS473, pS6 and p4E-BP1, was 
effectively inhibited (Figure S7A). We next treated cohorts of KPC mice from 10 weeks of 
age with gemcitabine, AZD2014 or AZD2014 in combination with gemcitabine. This 
timepoint was selected in order to mimic surgically resectable disease, and to exclude 
tumor-promoting effects that may not be evident when mice with late-stage disease are 
treated. In line with previous studies, gemcitabine treatment offered negligible benefit 
(Figure 6A). In contrast, AZD2014 treatment significantly delayed tumor progression. 
Combination of AZD2014 and gemcitabine further prolonged survival, and mice treated 
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with this combination had a median survival of 280 days compared with 147 days for 
those treated with gemcitabine alone (Figure 6A). These data were supported by our 
demonstration that AZD2014 and gemcitabine act synergistically to induce PDAC cell 
death in vitro (Figure S7B). When we assessed inhibition of mTOR targets by IHC we 
found that phosphorylation of both mTORC1 and mTORC2 targets was suppressed, 
although mTORC2 signaling was more efficiently inhibited (Figure 6B). Similar to KPC 
RictorΔ/Δ mice, we did not observe any differences in p21 expression upon AZD2014 
treatment, however we did observe a decrease in proliferation based on Ki67 staining, 
and as in KPC RictorΔlΔ tumors, we also observed slightly elevated nuclear p27 and 
decreased pERK (Figure 6C). Thus, we conclude that dual mTORC1/2 inhibition can 
effectively block signaling downstream of mTOR, and may hold promise as a novel 
therapeutic strategy in pancreatic cancer. 
 
Inhibition of mTORC1/2 prolongs survival in late stage tumors 
We also tested the effects of AZD2014 treatment in mice with late stage tumors. We 
monitored KPC mice until they exhibited clinical signs of PDAC, including swollen 
abdomen, cachexia, hunching, and the presence of a palpable tumor. At this stage mice 
were randomized onto treatment with vehicle, gemcitabine, AZD2014, or AZD2014 
combined with gemcitabine. We found that survival from the commencement of 
treatment was significantly prolonged by AZD2014 treatment (Figure 7A). Interestingly, 
combination of AZD2014 with gemcitabine did not further extend survival (Fig. 7A).  
When we assessed inhibition of mTOR targets by IHC we found that phosphorylation of 
downstream targets of both mTORC1 (S6, 4E-BP1) and mTORC2 (AKT, NDRG1) was 
suppressed (Figure 7B), although again, mTORC2 signaling was more efficiently 
suppressed. Although we saw an impact in a very aggressive late stage model, mice still 
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rapidly progressed to end stage disease. Consistent with this, in this late setting in vivo 
we did not observe induction of CDK inhibitors, nor did we observe changes in other 
potential targets of RICTOR such as c-MYC (37), showing that as tumors progress in vivo 
they become less susceptible to mTORC2 inhibition as a single agent. 
 
Inhibition of PI3K co-operates with mTORC1/2 inhibition to prolong survival in late-
stage tumor-bearing mice 
Recent studies have suggested that cancer cells can escape the requirement for mTOR 
through uptake of nutrients (38). In addition, mTORC1 inhibition results in feedback 
activation of the PI3K/AKT axis (39). Therefore, we tested whether inhibiting PI3K 
signaling could enhance the chemotherapeutic effects of AZD2014.  Previous elegant 
studies have shown deletion of PI3Kα blocked tumor formation but not tumor growth 
(9), consistent with our findings with Rictor gene deletion. Moreover Rac1 deletion 
strongly suppresses pancreatic carcinogenesis and this was suggested to be 
downstream of PI3K (40,41). Given Rac1 can also modify macropinocytosis, inhibiting 
PI3K may also suppress some of the mechanisms of nutrient uptake when mTOR is 
depleted. Since PI3Kβ is the primary isoform that links PI3K signaling to RAC1 (42), we 
combined AZD2014 with a PI3Kβ kinase inhibitor, AZD8186 (43). We first investigated 
whether AZD2014-AZD8186 co-treatment reduced KPC tumor cell viability in vitro 
(Figure S8A). AZD2014 proved potent in reducing cell viability (as observed previously 
with Rictor knockdown) and combined treatment with AZD8186 (which alone had little 
effect) further reduced cell viability (Figure S8A). Interestingly, in this scenario we were 
able to detect diminished Myc expression and p27 upregulation in the dual treated cell 
lines (Figure S8B). 
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Therefore, we decided to investigate the effects of inhibiting mTORC1/2 and PI3K in 
mice with late stage tumors. As previously, we monitored KPC mice until they exhibited 
symptoms of PDAC and a palpable tumor, and then treated with AZD2014 and/or 
AZD8186. We found that survival was extended by AZD2014 and AZD8186 co-treatment 
relative to treatment with either compound alone (Figure 7C). Taken together, our data 
show that Rictor-mediated signaling plays a crucial role in pancreatic cancer 
tumorigenesis. Moreover, mTORC2 inhibition, particularly as part of a combinatorial 
approach, potentially represents a new therapeutic strategy for this disease. 
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Discussion 
 
Pancreatic cancer is an almost universally lethal disease, and better understanding of 
the signaling pathways involved in its pathogenesis is required. Cytotoxic chemotherapy 
has limited efficacy, so the development of targeted therapeutic strategies is an 
attractive approach. Mutation of KRAS is almost universally the driving force in 
initiation. Indeed, inducible mouse models have demonstrated that pancreatic tumors 
retain dependence on activated KRAS signaling (44,45). Past attempts to directly inhibit 
KRAS have failed, however, inhibition of key signaling pathways downstream of KRAS 
may hold promise. Prior studies have shown PI3K signaling to be a key mediator of 
oncogenic KRAS in the pancreas (9). mTOR is one of the major effectors of PI3K, 
however, its involvement in pancreatic tumorigenesis has been relatively understudied. 
Clinical trials aimed at inhibiting mTORC1 have failed, and given the high cost of trials 
and the high attrition rate for most novel putative therapeutic agents, a greater 
understanding of how signaling through mTORC1 and mTORC2 contributes to 
pancreatic tumorigenesis is required. 
 
Here we demonstrate that genetic deletion of the mTORC2 complex component, Rictor, 
strongly suppresses pancreatic tumorigenesis. This anti-tumorigenic effect of Rictor 
deletion was associated with increased expression of CDK inhibitors, reduced 
proliferation, and features of senescence in vitro. Our findings are in line with recent 
studies in prostate cancer (19) and melanoma (46) that demonstrated a requirement for 
mTORC2 signaling. Importantly, while loss of Rictor significantly prolonged tumor 
latency in KPC mice, tumors ultimately progressed, and the anti-proliferative signals 
observed in pre-neoplastic lesions were lost in late-stage tumors, perhaps due to loss of 
 22
p53. Indeed, the presence of wild-type p53 may augment the anti-proliferative effects of 
mTOR inhibition (47). Our findings suggest that mTORC2 signaling plays an important 
role during pancreatic tumorigenesis. However, it remains possible that mTORC2-
independent functions of Rictor contribute to the observed phenotypes. Additional 
studies utilizing null alleles for other mTORC2 components would address this issue.  
 
Given our prior finding that pharmacologic inhibition of mTORC1 with rapamycin 
showed no efficacy in the ‘gold-standard’ KPC mouse model (23), recapitulating negative 
results using mTORC1 inhibitors in clinical trials, it was important to determine whether 
inhibition of both mTOR signaling complexes is an effective strategy. Our data using the 
mTOR kinase inhibitor AZD2014 demonstrate that blockade of mTOR signaling impairs 
the progression to end-stage disease and enhanced the benefit of gemcitabine. The 
mechanism for this cooperation is unclear, however, inhibition of mTOR signaling may 
reduce expression of the low-density lipoprotein receptor (LDLR) (48), and LDLR 
depletion can increase the efficacy of gemcitabine in KPC mice (49). It would be 
interesting in the future to compare directly the effects of clinically relevant mTORC1 
inhibitors with dual mTOR inhibitors. Nevertheless, our findings indicate that dual 
targeting of mTOR may represent a potential treatment strategy in PDAC. 
 
Dual targeting of mTORC1/2 has a number of benefits. mTORC2 signaling is almost 
completely abrogated in tumors from treated mice, similar to the effects we observed 
with Rictor deletion. Further, mTORC1 inhibition alone may actually enhance 
proliferation of activated KRAS-expressing cells in the setting of nutrient deprivation, by 
increasing the efficiency of utilization of extracellular proteins (38). Considering that 
PDAC is characterized by a dense stroma that may provide not only physical, but 
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nutritional support for tumor cells, it is perhaps not surprising that inhibition of 
mTORC1 alone is ineffective. It should also be noted that in all in vitro systems we found 
that AZD2014 or Rictor knockdown had profound effects on soft agar growth and tumor 
cell proliferation suggesting that the tumor microenvironment might also be the source 
of support for the late stage aggressive tumors.  
 
Molecularly targeted therapeutics often fail to display expected anti-tumor effects due to 
stimulation of feedback mechanisms. Indeed, mTOR inhibition can promote feedback 
activation of PI3K (39), which, in turn, can specifically activate mTORC2 through release 
of SIN1-mediated suppression of mTOR by PIP3 binding (50). Therefore, our finding that 
combined mTOR and PI3Kβ inhibition prolonged survival in mice with end-stage disease 
provides further support for the evaluation of mTOR kinase inhibitors in PDAC where 
most patients present with disseminated disease.   
 
The pathways downstream of mTORC2 signaling may also represent potential 
therapeutic targets. For example, in addition to AKT, mTORC2 signaling also regulates 
SGK1 (14) and PKCα (51). Increased expression of SGK has been observed in several 
cancer types, while cancer cell lines bearing PIK3CA mutations have been shown to be 
dependent on SGK (52). mTORC2 can also regulate PKCα and RAC (51,53), both of which 
potentially influence tumorigenesis by affecting the spatial control of cell growth.  In 
fact, RAC1 is reported to play an important role in KRAS-driven pancreatic 
tumorigenesis (40,41). MYC is also a reported target of mTORC2 (37), and we recently 
demonstrated that pancreatic tumorigenesis is significantly delayed by Myc deficiency 
(54).  Defining the relative contributions of these downstream molecules is required to 
determine the mechanisms underlying the requirement for mTORC2 signaling described 
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here. In addition, recent work demonstrated that the temporal sequence of drug 
delivery can dramatically alter cellular response (55). Therefore, it will be vital to 
determine the optimal sequence and timing of delivery of mTOR inhibitors (and other 
targeted drugs) when used in combination with each other or cytotoxic drugs such as 
gemcitabine.  
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Figure Legends 
 
Figure 1: Loss of Rictor impairs the development and progression of KrasG12D-
driven PanINs 
Histological evaluation of PanIN lesions in pancreata from 4-month (A, B) and 8-month 
old (C, D) KC and KC RictorΔ/Δ mice. (A) Representative images from H&E stained tissues, 
quadchrome stained tissues and Rictor RNAscope® stained tissues. The quadchrome 
stain marks collagen red, mucin blue, cytoplasm yellow-brown, and nucleic acids black. 
(B) Quantification of normal and neoplastic tissue as a percentage of total tissue area in 
4-month old KC and KC RictorΔ/Δ pancreata. (C) Representative images from H&E stained 
tissues, quadchrome stained tissues and Rictor RNAscope® stained tissues. (D) 
Quantification of normal and neoplastic tissue as a percentage of total tissue area in 8-
month old KC and KC RictorΔ/Δ pancreata. Student’s t test:  *p<0.05,  **p<0.01,  
***p<0.001. 
 
Figure 2:  mTORC2, but not mTORC1, is functionally absent in KC RictorΔ/Δ PanINs 
Immunostaining for pAKT, pNDRG1, pERK and pSGK1 in pancreata from 8-month old KC 
and KC RictorΔ/Δ mice (200x magnification). 
 
Figure 3: Rictor-deficient PanINs display increased nuclear expression of CDK 
inhibitors and decreased nuclear expression of BMI1   
(A-D) Quantification of nuclear staining in PanIN1 lesions in 4- (left) and 8- (right) 
month old KC and KC RictorΔ/Δ mice. (A) p16Ink4a, (B) p21Cip, (C) p27Kip1 and (D) BMI1. 
**p<0.01,  ***p<0.001 as determined by student’s t-test in individual comparisons of 
cohorts. (E) Doubling time of a PanIN-derived cell line 4-6 days following shRNA-
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mediated Rictor knockdown. P values determined by counter variance analysis of 
inverse slopes. (F) Senescence-associated β-galactosidase positivity in a PanIN-derived 
cell line 4 days following shRNA-mediated Rictor knockdown. **p<0.01,  ***p<0.001 as 
determined by student’s t-test. 
 
Figure 4: Rictor deletion impairs the progression of pancreatitis-induced PanINs  
(A) H&E and quadchrome staining of pancreata from KC and KC RictorΔ/Δ mice harvested 
2 or 21 days following injection of caerulein or PBS (100x magnification). (B) 
Quantification of normal and neoplastic tissue as a percentage of total tissue area in 
pancreata from KC and KC RictorΔ/Δ mice 21 days post-caerulein injection (n=5-6 mice 
per cohort). (C) IHC for pAKTS473, pAKTT308, and pERK1/2T202/Y204 in pancreata from KC 
and KC RictorΔ/Δ mice 21 days post-caerulein injection (200x magnification). (D-G) 
Quantification of positive nuclei in PanIN1 lesions in KC and KC RictorΔ/Δ pancreata 21 
days post-caerulein injection. (D) p16Ink4a, (E) p21Cip, (F) p27Kip1 and (G) BMI1. Student’s 
t test:  *p<0.05,  **p<0.01,  ***p<0.001. 
 
Figure 5: Rictor deletion delays tumor formation in a mouse model of pancreatic 
cancer  
(A) Kaplan-Meier survival analysis showing PDAC-free survival in KPC, KPC RictorΔ/+, 
and KPC RictorΔ/Δ mice. Ticks indicate mice censored due to extra-pancreatic 
pathologies. p values determined by Log Rank test comparing individual cohorts 
separately. (B) RNAscope® showing absence of Rictor in tumors from KPC RictorΔ/Δ 
(spleen shown as positive control) compared with KPC mice. (C) IHC for downstream 
mTOR signaling pathway components in KPC and KPC RictorΔ/Δ tumors as indicated. (D) 
IHC for Ki67, p21, p27 and pERK in KPC and KPC RictorΔ/Δ tumors as indicated. 
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Figure 6: Pharmacological inhibition of mTORC1/2 delays tumor formation in KPC 
mice  
(A) Kaplan-Meier survival analysis showing PDAC-free survival in KPC mice treated 
from 10w with AZD2014, Gemcitabine, or AZD2014+Gemcitabine. Ticks indicate mice 
censored due to extra-pancreatic pathologies. p values determined by Log Rank test 
comparing individual cohorts separately. (B) IHC for downstream mTOR signaling 
pathway components in tumors from AZD2014-treated and untreated KPC mice as 
indicated. (C) IHC for Ki67, p21, p27 and pERK in KPC and KPC RictorΔ/Δ tumors as 
indicated. 
 
Figure 7: Pharmacological inhibition of mTORC1/2 prolongs survival in mice with 
late stage tumors  
(A) Kaplan-Meier survival analysis showing survival in KPC mice treated from the onset 
of symptoms with vehicle (n=4), AZD2014 (n=8), or AZD2014+Gemcitabine (n=6). (B) 
IHC for downstream mTOR signaling pathway components in treated and untreated KPC 
tumors as indicated. (C) Kaplan-Meier survival analysis showing survival in KPC mice 
treated from the onset of clinical symptoms with vehicle (n=4), AZD2014 (n=8), 
AZD8186 (n=4), or AZD2014+AZD8186 (n=5). P values calculated by Log Rank test. 







